Amgen Inc. (AMGN)
Amgen Is Redoubling Its Efforts To Take On Weight-Loss Kingpins Novo, Lilly
Amgen stock fell late Tuesday after the biotech reported lighter-than-expected second-quarter profits, though sales beat.
Amgen second quarter profit dips, sales rise 20%
Amgen on Tuesday said its second-quarter profit slipped 1% as higher expenses offset a 20% increase in revenue driven by the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics.
Amgen Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Amgen Inc. AMGN is expected to release earnings results for its second quarter, after the closing bell on Tuesday, Aug. 6.
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
3 Biotech Stocks That Could Have Investors Grinning Soon
Investing in biotech stocks is a thrilling ride. These innovative businesses developing breakthrough drugs can generate enormous profits for investors but also destroy significant value if their investigational therapies fail to make it to market.
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
Amgen is developing a promising anti-obesity candidate. This product could be a blockbuster by 2030.
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
Amgen (AMGN) closed at $335.53 in the latest trading session, marking a +0.92% move from the prior day.
Exploring Analyst Estimates for Amgen (AMGN) Q2 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
The Top 3 Biotech Stocks to Buy Now Summer 2024
In the bustling world of biotechnology, innovation remains the cornerstone of growth. Some biotech stocks, known for their groundbreaking research and rapid adaptation to health challenges, are particularly well-positioned to do well in the future.
Can Amgen (AMGN) Keep the Beat Streak Alive in Q2 Earnings?
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy?
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (AMGN) Advances But Underperforms Market: Key Facts
In the closing of the recent trading day, Amgen (AMGN) stood at $334.85, denoting a +0.16% change from the preceding trading day.
